公司名稱: 先健科技公司 (在開曼群島註冊成立的有限公司) FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 呈交日期: 2025年12月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01302 | 說明 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | 40,000,000,000 | USD | 0.00000125 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | USD | | 0 | | 本月底結存 | | 40,000,000,000 | USD | 0.00000125 | USD | | 50,000 | 本月底法定/註冊股本總額： U ...

Investment Rating - The report maintains a positive outlook on the innovative drug sector, indicating a rebound and potential for further growth in the upcoming months [3][6]. Core Insights - The innovative drug sector is expected to see a rebound after previous adjustments, with significant catalysts anticipated in December and January. The results of the national medical insurance negotiations will be released in early December, which may impact the inclusion of domestic innovative drugs in the insurance catalog [3][14]. - The upcoming American Society of Hematology (ASH) conference from December 6-9 is highlighted as a key event, with multiple differentiated hematology products expected to present new data [3][4][42]. - The CXO sector shows a continuous upward trend, supported by the rapid growth of new orders and backlog, ensuring performance release in the next 1-2 years [4][53]. Summary by Sections Innovative Drugs - The report emphasizes the importance of focusing on dual/multi-target drugs for various cancers and chronic diseases, as well as opportunities in ADCs and small nucleic acid therapies [6][15]. - The report notes that the innovative drug financing data is showing marginal improvement, indicating a potential recovery in the sector [6][15]. Biologics - The report mentions positive preliminary results from the Phase II clinical trial of amycretin for Type 2 diabetes, suggesting continued monitoring of its clinical progress [4][46]. Medical Devices - The report highlights the emergence of innovative domestic medical devices, with expectations for profit margins to stabilize and improve as new products are approved [5]. Traditional Chinese Medicine & Pharmacies - The report suggests monitoring companies with strong brand power and good inventory management, such as China Resources Sanjiu and Jichuan Pharmaceutical, due to rising flu incidence [5]. Medical Services and Consumer Healthcare - The report discusses a collaboration between a traditional Chinese medicine group and a local health bureau to enhance the capabilities of grassroots medical services through technology [5]. Key Investment Targets - The report identifies key companies to watch, including Innovent Biologics, Kintor Pharmaceutical, and others in the innovative drug and medical device sectors [7].

Group 1 - The company announced the resignation of Ms. Huan Xingmei as an executive director and member of the nomination committee effective November 21, 2025 [1] - Mr. Liang Xianzhi has resigned as an independent non-executive director, chairman of the audit committee, and member of both the nomination committee and the remuneration committee [1] - Ms. Wu Liping and Mr. Fang Yu have been appointed as executive directors [1] Group 2 - Mr. Feng Xiaoling has been appointed as an executive director and member of the nomination committee [1] - Ms. Chen Dongxia has been appointed as an independent non-executive director, chairman of the audit committee, and member of both the nomination committee and the remuneration committee [1]

Group 1 - The company announced changes in its board of directors effective from November 21, 2025 [1] - Xuanying Mei will resign as an executive director and member of the nomination committee [1] - Liang Xianzhi will resign as an independent non-executive director, chairman of the audit committee, and member of both the nomination and remuneration committees [1] - Wu Liping and Fang Yu have been appointed as executive directors [1] - Feng Xiaoling has been appointed as an executive director and member of the nomination committee [1] - Chen Dongxia has been appointed as an independent non-executive director, chairman of the audit committee, and member of both the nomination and remuneration committees [1]

香港交易及結算所有限公司與香港聯合交易所有限公司對本公佈的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不就因本公佈全部或任何部分內容而產生或因依賴該等內容 而引致的任何損失承擔任何責任。 LifeTech Scientific Corporation 先健科技公司 （在開曼群島註冊成立的有限公司） （股份代號：1302） 董事名單與其角色和職能 王皖松 周路明 陳東霞 – 1 – 本公司成立三個董事會委員會，及其成員如下： 先健科技公司（「本公司」）董事會（「董事會」）成員載列如下： 執行董事 謝粵輝 （主席兼首席執行官） 劉劍雄 （常務副總裁、首席財務官兼公司秘書） 吳麗萍 方宇 馮小玲 非執行董事 姜峰 獨立非執行董事 – 2 – 陳東霞 審核委員會 薪酬委員會 提名委員會 | 陳東霞 | （主席） | 王皖松 | （主席） | 周路明 | （主席） | | --- | --- | --- | --- | --- | --- | | 周路明 | | 謝粵輝 | | 謝粵輝 | | | 王皖松 | | 陳東霞 | | 馮小玲 | | | | | | | 王皖松 | | 承董事會命 先健科 ...

香港交易及結算所有限公司與香港聯合交易所有限公司對本公佈的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不就因本公佈全部或任何部分內容而產生或因依賴該等內容 而引致的任何損失承擔任何責任。 LifeTech Scientific Corporation 先健科技公司 （在開曼群島註冊成立的有限公司） （股份代號：1302） 更改董事及董事會委員會組成 先健科技公司（「本公司」，連同其附屬公司統稱為「本集團」）董事（「董事」，及各 自為一名「董事」）會（「董事會」）謹此宣佈，自二零二五年十一月二十一日起： (iii) 吳麗萍女士（「吳女士」）及方宇先生（「方先生」）各自已獲委任為執行董事； (iv) 馮小玲女士（「馮女士」）已獲委任為執行董事及提名委員會成員；及 獨立非執行董事辭任 董事會已自梁先生收到辭任函，當中彼提呈自二零二五年十一月二十一日起辭任獨 立非執行董事及審核委員會主席以及提名委員會及薪酬委員會各自成員之職務，以 滿足聯交所有關任職超九年長期擔任獨立非執行董事之規定。 梁先生確認，彼於任何方面與本公司或董事會概無分歧，亦無有關彼辭任之事宜須 提請股東或聯交所垂注。董事會謹此誠摯感 ...

Core Viewpoint - The company has received official approval from the National Medical Products Administration of China for its G-BranchTM thoracoabdominal aortic stent graft system, which is designed for the treatment of thoracoabdominal aortic aneurysms (TAAA) [1][2] Group 1 - The G-BranchTM system is a pioneering product featuring a "dual inner and dual outer" hybrid branch design, allowing for full endovascular reconstruction of TAAA while maintaining blood supply to vital organs during the procedure [1] - The company holds independent intellectual property rights for the G-BranchTM product, which is expected to provide a systematic solution for TAAA patients [1] - The approval of the G-BranchTM system follows the earlier approvals of the aortic arch stent system and aortic covered stent system, enhancing the company's product portfolio in the peripheral vascular intervention field [2] Group 2 - The company aims to offer more flexible, comprehensive, safe, effective, and easy-to-operate solutions for thoracoabdominal aortic aneurysm endovascular reconstruction as commercialization progresses [2] - The company is committed to collaborating with industry experts to advance the development and launch of more urgently needed medical device products, driving growth in the medical device sector [2]

Core Viewpoint - The company has received official registration approval from the National Medical Products Administration of China for its G-BranchTM thoracoabdominal aortic stent graft system, developed in collaboration with a team from the First Medical Center of the Chinese People's Liberation Army General Hospital, marking a significant advancement in the treatment of thoracoabdominal aortic aneurysms (TAAA) [1][2] Group 1 - The G-BranchTM system is designed for the treatment of TAAA involving the celiac trunk, superior mesenteric artery, and bilateral renal arteries, enabling complete endovascular reconstruction of the thoracoabdominal aorta [1] - The product features a world-first "dual inner and dual outer flip" hybrid branch design, with different diameters for the upper and lower segments of the stent body, aligning with the starting positions of the body's visceral branch vessels [1] - The company holds independent intellectual property rights for the G-BranchTM product, which is expected to provide a systemic solution for TAAA patients through a fully endovascular approach, promising less trauma, simpler operation, and better adaptability [1] Group 2 - Following the approval of the aortic arch stent system and aortic covered stent system in the first half of 2025, the G-BranchTM product further enriches the company's product portfolio in the peripheral vascular intervention field [2] - The company is positioned as a leading innovative enterprise globally with a complete endovascular repair solution for the aorta, enhancing its commercial offerings [2] - The ongoing commercialization process aims to provide more flexible, comprehensive, safe, effective, and easy-to-operate solutions for thoracoabdominal aortic aneurysm reconstruction, while collaborating with industry experts to advance the development and launch of urgently needed medical devices [2]

Core Viewpoint - The announcement by Xianjian Technology (01302.HK) regarding the approval of the G-Branch™ thoracoabdominal aortic stent-graft system by the National Medical Products Administration of China signifies a significant advancement in the treatment of thoracoabdominal aortic aneurysms (TAAA) [1] Group 1 - The G-Branch™ system is developed in collaboration with Professor Guo Wei's team from the First Medical Center of the Chinese People's Liberation Army General Hospital [1] - The product is specifically designed for the treatment of TAAA involving the celiac trunk, superior mesenteric artery, and bilateral renal arteries [1] - The system enables complete endovascular reconstruction of thoracoabdominal aortic aneurysms [1]

香港交易及結算所有限公司與香港聯合交易所有限公司對本公佈的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不就因本公佈全部或任何部分內容而產生或因依賴該等內容 而引致的任何損失承擔任何責任。 LifeTech Scientific Corporation 先健科技公司 （在開曼群島註冊成立的有限公司） （股份代號：1302） 自願性公佈 G-BranchTM胸腹主動脈覆膜支架系統 獲得中國國家藥品監督管理局的正式註冊批准 本公佈乃由先健科技公司（「本公司」，連同其附屬公司稱為「本集團」）自願作出，旨 本公司董事（「董事」）會（「董事會」）欣然宣佈，於二零二五年十一月六日，由中國人 民解放軍總醫院第一醫學中心郭偉教授團隊與本集團聯合研發的 G-BranchTM胸腹主 動脈覆膜支架系統（「G-BranchTM」或「該產品」）獲中國國家藥品監督管理局（「國家 藥品監督管理局」）正式註冊批准。該產品適用於胸腹主動脈瘤（「TAAA」）累及腹腔 病變類型之一，瘤體一旦破裂，患者死亡率高達 95%。傳統開放手術風險極高， 創傷巨大，胸腹聯合切口可長達 1 米，手術耗時需 12 個小時，手術全身縫合超過 1, ...